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Abstract
Cancer cells are able to survive in difficult conditions, reprogramming their metabolism
according to their requirements. Under hypoxic conditions they shift from oxidative phos-
phorylation to aerobic glycolysis, a behavior known asWarburg effect. In the last years, gly-
colytic enzymes have been identified as potential targets for alternative anticancer
therapies. Recently, phosphoglycerate kinase 1 (PGK1), an ubiquitous enzyme expressed
in all somatic cells that catalyzes the seventh step of glycolysis which consists of the revers-
ible phosphotransfer reaction from 1,3-bisphosphoglycerate to ADP, has been discovered
to be overexpressed in many cancer types. Moreover, several somatic variants of PGK1
have been identified in tumors. In this study we analyzed the effect of the single nucleotide
variants found in cancer tissues on the PGK1 structure and function. Our results clearly
show that the variants display a decreased catalytic efficiency and/or thermodynamic stabil-
ity and an altered local tertiary structure, as shown by the solved X-ray structures. The
changes in the catalytic properties and in the stability of the PGK1 variants, mainly due to
the local changes evidenced by the X-ray structures, suggest also changes in the functional
role of PGK to support the biosynthetic need of the growing and proliferating tumour cells.
Introduction
Carcinomas are the most common type of cancer. According to the American Cancer Society,
in 2016 the overall estimate is of 1685210 new cases of cancer worldwide and among them
61000 cases of female breast carcinoma in situ are expected [1]. Cancer cells are able to adapt
to survive in difficult conditions, like for example in O2 deficiency, through a reprogramming
of their metabolic machinery according to their requirements [2]. Among these, the hallmark
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of the metabolic reprogramming is the shift from oxidative phosphorylation to aerobic glycol-
ysis that allows tumor cells to survive under hypoxic conditions [3], an adaptative behaviour
described nearly 100 years ago and known as the Warburg effect. In the last years, glycolytic
enzymes, and their role in cancer metabolism, have been the object of several studies and they
have been identified as potential targets for alternative anticancer therapies [4, 5].
A central enzyme in glycolysis is the phosphoglycerate kinase 1 (PGK1). This ubiquitous
glycolytic enzyme is expressed in all somatic cells, where it provides energy in form of ATP
through the reversible phosphotransfer reaction from 1,3-bisphosphoglycerate (1,3-BPG) to
MgADP in order to produce 3-phosphoglycerate (3-PG) and MgATP in the presence of free
magnesium [6,7]. Deficiency of PGK1 has been associated with hereditary non-spherocytic
haemolytic anaemia (HNSHA), a rare disorder that is caused by a variety of inherited defects
in glycolysis [8].
The structure of human PGK1 was solved in the open conformation (PDB code: 2XE7) [7]
in the partially closed conformation (PDB code: 2ZGV) [9] and in closed conformation bound
to a transition state analogue (PDB code: 2WZB) [10] as well as in complex with inhibitors
(PDB codes: 4O33, 4O3F) [11]. PGK1 is a monomeric enzyme of 417 amino acids formed by
two distinct α-helical domains of equal size, the N- and C-terminal domains connected by a
hinge region (Fig 1). The N-terminal domain binds 3-PG or 1,3-BPG while the C-terminal
domain binds MgADP or MgATP. During the catalytic cycle four hinge points mediate inter-
domain motions that result in the flexible region bending, allowing the two domains to
approach each other bringing the catalytic residues in the right position. During this transition
phase, a large number of conformational rearrangements, triggered by the simultaneous bind-
ing of the two substrates, lead the enzyme from its open form, which has the highest affinity
for the substrates, to its closed form in which the enzyme performs the transfer of the phospho-
ryl group fulfilling its catalytic activity [6].
Interestingly, similarly to many other glycolytic enzymes, PGK1, in addition to its metabolic
function, may acquire different functions. This enzyme may be secreted in the extracellular
environment by tumour cells and act as a thiol reductase regulating angiogenesis [12]. In addi-
tion, translocation of PGK1 to the nucleus is related to binding to alpha DNA polymerase [13].
Notably, under hypoxic conditions, PGK1 may translocate from cytoplasm to mitochondrion
where it may act as a protein kinase and phosphorylate different protein substrates [14]. Inter-
estingly, the protein kinase activity of PGK1 has been related to initiation of autophagy [15, 16].
PGK1 is regulated by hypoxia-induced factor-1α (HIF-1α), the most important factor
involved in the cellular response to hypoxia [12]. Several solid tumors like prostate cancer,
breast cancer, pancreatic ductal adenocarcinoma, multidrug-resistant ovarian cancer and met-
astatic gastric cancer exhibit an increased expression of glycolytic enzymes such as PGK1 to
generate ATP in hypoxic conditions [17±21]. The elevated levels of PGK1 protein, detected in
the serum of patients affected by pancreatic cancer [22, 23] and in breast cancer tissues [23],
suggest a plausible use of PGK1 as a cancer biomarker. Indeed, despite all the observations that
report PGK1 overexpression in many cancer types, the role of this enzyme in tumorigenesis is
yet unclear [14].
In different cancer types, somatic mutations of PGK1 have been identified, as reported in
COSMIC (Catalogue of Somatic Mutations in Cancer) (http://cancer.sanger.ac.uk/cosmic), a
database which collects somatic mutation identified in human cancers [24]. Most of these vari-
ants are missense ones, also known as nonsynonymous single nucleotide variants (nsSNVs),
occurring in the coding region and leading to a polypeptide sequence with amino acid substi-
tutions [25]. By controlling ATP and 3-PG levels, PGK1 plays an important role in coordinat-
ing energy production with biosynthesis and redox balance, so mutations of this enzyme can
be responsible for alterations of metabolic profile in different cancer cell lines.
PGK1 variants in cancer
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The effect of nsSNVs on protein stability, protein-protein interactions and protein func-
tions has been investigated for several other protein families [26±29]. Indeed, large-scale
computational studies utilizing structural information indicate that a single amino acid
Fig 1. Amino acid sequence and structure of PGK1. N-terminal domain (violet), C-terminal domain (green), hinge
region (blue) (PDB: 2XE7, open conformation). (A) Secondary structural elements are shown at the top of the amino
acid sequence. Mutated residues are depicted in bold red. The dots under the sequence represent the residues involved
in 3-PG or 1,3-BPG binding (pink dot) and in ATP or ADP binding (green dot). (B) Location of the mutations on
PGK1 structure (open conformation). Mutated residues are depicted in scaled ball and stick and 3-PG and ADP in
stick.
https://doi.org/10.1371/journal.pone.0199191.g001
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substitution will affect either protein-protein interactions and protein stability [30, 31]. Analy-
sis of physico-chemical properties of natural variants may be helpful to reveal local structural
changes that may not affect the overall folding of the structure [28]. Thus, only a detailed
experimental analysis can unequivocally reveal the effect of the missense mutations on protein
function and/or stability [32].
In this study we selected seven PGK1 nsSNVs found in cancer tissues and annotated in the
COSMIC database. The mutated residues are located in the 3-PG binding site, in the flexible
hinge region that allows the two domains of the enzyme to approach during the catalytic cycle,
and in the MgADP binding site in the C-terminal domain (Fig 1). Herewith we report the
effects of nsSNV on PGK1 by analysing the impact of single amino acid replacements on the
variants structure, on their conformational stability, and on their catalytic activity compared
to the wild type protein.
Materials andmethods
Plasmids and site-directed mutagenesis
PGK1 wild type plasmid was kindly provided by Dr. Maristella Maggi, University of Pavia
[PMID: 22348148]. Quick Change Site-Directed Mutagenesis Kit (Stratagene) was used to
introduce single mutations in the gene encoding for the wild type PGK1 and inserted into the
plasmid backbone. The mutagenic oligonucleotides used to obtain the seven selected variants
(i.e, R38M, R65W, G166D, M189I, A199V, V216F, and F241S) are listed in S1 Table.
The presence of the desired mutations and the absence of unwanted additional mutations
were confirmed by plasmid sequencing of the insert.
Protein expression and purification
Recombinant PGK1 protein has been expressed and purified as described in [33] with minor
modifications. PGK1 wild type and mutants were expressed in E. coli strain BL21(DE3). 15 mL
of overnight culture containing 100 µg/mL ampicillin were used to inoculate 500 mL LB cul-
tures containing ampicillin as antibiotic at a final concentration of 50 µg/mL. Cultures were
grown at 37ÊCuntil optical density at 600 nm (OD600) reached 0.6, at which point the protein
expression was induced by adding 0.5 mM isopropyl-β-D-thiogalactoside (Sigma-Aldrich).
Induced cultures were grown at 37ÊCfor 5 h in vigorous shaking. At the end of induction, cells
were collected by centrifugation and the pellet frozen.
To purify the enzymes, cells were resuspended in 45 mL of Binding buffer (20 mM Tris-
HCl pH 8.0, 1 mM EDTA, 1 mM tris(2-carboxyethyl)phosphine (TCEP)) containing a cocktail
of EDTA-free protease inhibitors (Sigma-Aldrich) and disrupted by sonication in a Vibracell
sonicator with 5 s boosts and 9 s pause, on ice. The lysate was cleared by centrifugation at
15000 rpm and the supernatant, after an additional centrifugation, was applied to a DEAE-Se-
pharose FF column (GE Healthcare) previously equilibrated in Binding buffer, to remove
endogenous protein contaminants and nucleic acids. In the above described conditions, the
recombinant PGK1, eluted in the unbound fraction, was concentrated to 2 mL using an Ami-
con concentrator Ultra-15 (Millipore). In order to remove protein aggregates, concentrated
protein was loaded onto a Superdex 200 300/10 gel filtration column equilibrated in 20 mM
Tris-HCl pH 8.0, 1 mM EDTA, 200 mM NaCl, 2 mM DTT using an AKTA FPLC system (GE
Healthcare). The protein was eluted by isocratic flow at 1.0 mL/min. 2 mL fractions were col-
lected and purity and molecular weight of the protein were checked by SDS±PAGE on a pre-
casted NuPage 4±12%bis-Tris polyacrylamide gel (Invitrogen). Gels were stained with Coo-
massie blue R-250. Protein concentration was determined spectrophotometrically using a
molar absorptivity coefficient (ε280) corresponding to 33460 M
-1cm-1 for the variant R65W
PGK1 variants in cancer
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and 28335 M-1cm-1 for wild type and the other variants, based on a molecular mass of 44.615
kDa, and calculated according to Gill and Hippel [34]. Pure protein was used for all structural
and stability experiments. The enzyme obtained from 1 liter culture was approximately 65 mg
in the case of wild type. High level of expression, ranging from 50 mg (V216F and F241S) to 87
mg (R38M), was obtained for all the mutant enzymes too.
Spectroscopic measurements
Intrinsic fluorescence emission measurements were recorded at a protein concentration of
110 µg/mL for the R65W variant and 130 µg/mL for wild type and all the other variants (0.08
AU280nm), in 20 mM Tris-HCl pH 8.0, 200 mM NaCl and 0.2 mMDTT, in a LS50B spectroflu-
orimeter (Perkin-Elmer) using a 1.0 cm path length quartz cuvette. Intrinsic fluorescence
emission spectra were recorded from 300 to 450 nm (1 nm sampling interval), with the excita-
tion wavelength set at 295 nm. Far-UV (190±250 nm) CD spectra were monitored at 20ÊCat a
protein concentration ranging over 130±170 µg/mL, using a 0.1 cm path length quartz cuvette,
in 20 mM Tris-HCl pH 8.0, 200 mM NaCl and 0.2 mMDTT. Near-UV (250±320nm) CD
spectra were recorded in a 1.0 cm path length quartz cuvette at a protein concentration rang-
ing between 1.50 and 1.70 mg/mL, in 20 mM Tris-HCl pH 8.0, 200 mM NaCl, 1.0 mM EDTA
and 2.0 mM DTT. CD measurements were carried out in a JASCO-815 spectropolarimeter
(Jasco, Easton, MD, USA) and the results are expressed as the mean residue ellipticity ([Θ]),
assuming a mean residue molecular mass of 110 per amino acid residue. All spectroscopic
measurements were carried out at 20ÊC.
Enzyme activity assay and kinetic studies
PGK1 activity was determined at 20ÊC,with 3-PG and MgATP as substrates, by glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) coupled spectrophotometric assay according to
[33]. The standard reaction mixture contained 100 mM Tris-HCl pH 8.0, 0.5 mM EDTA, 2
mMMgCl2, 0.24 mM NADH, 4U/0.5mL GAPDH, 15.0 mM 3-PG, and 5.0 mMMgATP, in a
final volume of 0.5 mL. Kinetic parameters for PGK1 activity towards 3-PG were determined
at 20ÊCby using at least 10 different concentrations of 3-PG under conditions identical to
those described above, at 5.0 mMMgATP fixed substrate concentration. The reaction was
started by adding different amounts of PGK1 ranging from 4 ng to 20 µg. All measurements
were performed in triplicate in a Lambda 16 computerized spectrophotometer (Perkin-
Elmer). Kinetic data were analysed according to [33], using GraphPadPrism 5.04. Results are
reported as the mean of three experiments from different protein preparations.
Temperature dependence of PGK1 activity
The activity assay mixture, containing 100 mM Tris-HCl pH 8.0, 0.5 mM EDTA, 2 mM
MgCl2, 0.24 mM NADH, 4U/0.5mL GAPDH, 5.0 mMMgATP and 0.2 mM 3-PG in 0.5 mL
final volume, was incubated at increasing temperature in a thermostated cuvette. 4 µL of pure
enzyme, at 10ÊC,were added to 0.5 mL of the assay mixture equilibrated at the desired temper-
ature to start the reaction. The final enzyme concentration was 0.18±12.0 nM. The solution
was mixed in the thermostated cuvette and the absorbance at 340 nm was continuously moni-
tored for 10 min. The changes of enzyme activity as a function of temperature was fitted nonli-
nearly to the Arrhenius equation using GraphPadPrism 5.04 to obtain the activation energies
(Ea) for the catalytic reaction
k ¼ Ae  Ea=RT ð1Þ
PGK1 variants in cancer
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where k (s-1) is the rate constant at temperature T (K), A is a reaction specific quantity, R the
gas constant (1.987 cal x mol-1 x K-1) and Ea the activation energy of the reaction, as described
in [27].
Urea-induced unfolding equilibrium
PGK1 wild type and variants (110±160 µg/mL final concentration) were incubated at 20ÊCat
increasing concentrations of urea (0−8 M) in 20 mM Tris-HCl pH 8.0, 200 mM NaCl, 5.0 mM
MgCl2 and 0.2 mMDTT. After 10 min, a time sufficient to reach equilibrium, intrinsic fluores-
cence emission and far-UV CD spectra (0.2-cm cuvette) were recorded in parallel at 20ÊC.To
test the reversibility of the unfolding, PGK1 wild type and variants were unfolded at 20ÊCin
7.5 M urea at protein concentration ranging over 1.10±1.60mg/mL in 20 mM Tris-HCl, pH
8.0, in the presence of 2 mM DTT, 5 mMMgCl2 and 200 mMNaCl. After 10 min, refolding
was started by 10-fold dilution of the unfolding mixture at 20ÊCinto solutions of the same
buffer used for unfolding containing decreasing urea concentrations. The final protein con-
centration was 110±160 µg/mL. After 2 h, intrinsic fluorescence emission and far-UV CD
spectra were recorded at 20ÊC.All denaturation experiments were performed in triplicate.
Thermal stability
PGK1 wild type and variants (110±160 µg/mL) were heated from 20ÊCto 80ÊCin 20 mM Tris-
HCl, pH 8.0, 200 mM NaCl, 0.2 mM DTT, in a 0.1 cm quartz cuvette with a heating rate of 1
degree x min-1 controlled by a Jasco programmable Peltier element as described in [27, 29].
The dichroic activity at 222 nm and the photomultiplier were continuously monitored in par-
allel every 0.5ÊC[35]. The solvent contribution at the various temperatures was taken into con-
sideration for all thermal scans. Melting temperature (Tm) values were calculated by taking the
first derivative of the ellipticity at 222 nm with respect to temperature, as described in [29]. All
denaturation experiments were performed in triplicate.
Data analysis
Far-UV CD spectra recorded as a function of urea concentration were analyzed by a singular
value decomposition algorithm (SVD) using the software MATLAB (Math-Works, South
Natick, MA) to remove the high frequency noise and the low frequency random errors and
determine the number of independent components in any given set of spectra, as described in
[27].
The changes in intrinsic fluorescence emission spectra at increasing urea concentrations
were quantified as the intensity-averaged emission wavelength, ðlÞ, [36] calculated according
to
l ¼ SðIiliÞ=SðIiÞ ð2Þ
where λi and Ii are the emission wavelength and its corresponding fluorescence intensity at
that wavelength, respectively. This quantity is an integral measurement, negligibly influenced
by the noise, which reflects changes in the shape and position of the emission spectrum.
Urea-induced equilibrium unfolding transitions monitored by far-UV CD ellipticity and
intrinsic fluorescence emission changes were analysed by fitting baseline and transition region
data to a two-state linear extrapolation model [37] according to
DGunfolding ¼ DG
H2O þm½Urea ¼   RTlnKunfolding ð3Þ
where ΔGunfolding is the free energy change for unfolding for a given denaturant concentration,
PGK1 variants in cancer
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DGH2O the free energy change for unfolding in the absence of denaturant andm a slope term
which quantifies the change in ΔGunfolding per unit concentration of denaturant, R the gas con-
stant, T the temperature and Kunfolding the equilibrium constant for unfolding. The model
expresses the signal as a function of denaturant concentration:
yi ¼
yN þ sN½Xi þ ðyU þ sU½XiÞ
exp½ð  DGH2O   m½XiÞ=RT
1þ exp ð  DG
H2O   m½XiÞ
RT
h i ð4Þ
where yi is the observed signal, yU and yN are the baseline intercepts for unfolded and native
protein, sU and sN are the baseline slopes for the unfolded and native protein, [X]i the denatur-
ant concentration after the ith addition, DGH2O the extrapolated free energy of unfolding in the
absence of denaturant,m the slope of a ΔGunfolding versus [X] plot. The denaturant concentra-
tion at the midpoint of the transition, [Urea]0.5, according to Eq (3), is calculated as:
½Urea
0:5
¼ DGH2O=m ð5Þ
All unfolding transition data were fitted by using Graphpad Prism 5.04.
Variants crystallization, data collection, structures solution
The protein samples used for crystallization trials contained PGK1 variants at a concentration
of 12±18mg/mL in Tris-HCl 20 mM pH 7.0, in the presence of 10 mM ADP, 25mMMgCl2,
50 mM 3-PG and 10 mM DTT. Crystals were obtained at 298 K by the hanging-drop vapour
diffusion method, sealing symmetric drops (1.0+1.0 µL) over 500 µL of reservoir solution.
We performed crystallization experiments with the PGK1 variants V216F, G166D, M189I,
R38M in order to obtain the structure of the protein-ligands complexes in both closed and par-
tially closed conformation. The detailed crystallization conditions for all the structures solved
are indicated in S2 Table. First we tested the conditions reported in the literature for the par-
tially closed conformation of wild type PGK1 [9] based on Na/K phosphate, obtaining diffract-
ing crystals (0.1 × 0.2 × 0.3 mm3) for V216F and M189I. Then a high throughput
crystallization screening (HTS) approach was employed for G166D and R38M variants. The
crystallization robot (Crystal Phoenix, Art Robbins Instruments) available at the bio-crystal
facility at the IBPM-CNR (c/o Department of Biochemical Sciences, Sapienza University of
Rome) allowed us to set up up-to crystallization trials using commercial crystallization kits
(Crystal Screens I, II, Wizard I, II and Index HT, Hampton Research). The best crystals of
R38M and G166D mutants have been obtained in sodium citrate. We also tried to crystallize
the closed form of the mutants by adding 20 mM NH4F in the protein solutions defined above
in order to mimic the transition state of the enzyme. Again we first tested the conditions
already reported for the wild type PGK1 [10], obtaining crystals only for the M189I mutant.
Then we performed HTS with the other mutants without success.
A single-wavelength data set was collected at 100 K from each crystal and processed with
XDS [38] and Aimless [39]. The structures were determined by molecular replacement with
the program MOLREP (CCP4 suite) [40] using the PDB entries 2WZB and 2ZGV as search
models for closed and partially closed conformations respectively. Refinement has been per-
formed using the maximum-likelihood method with the program REFMAC [41] and model
building has been done by using Coot [42]. Crystal parameters, beamlines specifications, data
collection parameters and refinement statistics are reported in S2 Table.
PGK1 variants in cancer
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Results
In this study we selected seven PGK1 variants (R38M, R65W, G166D, M189I, A199V, V216F
and F241S) mined from the COSMIC database (http://cancer.sanger.ac.uk/cosmic) [24] and
associated to human carcinoma. Most of these PGK1 variants, M189I, A199V, V216F and
F241S (Fig 1), are reported to be found in breast carcinoma; the other variants, R38M, R65W
and G166D are reported to be present in lung, liver and endometrium carcinoma. The location
of the selected mutants mapped onto the PGK1 structure is shown in Fig 1. Residues R38, R65
and G166 are located in the enzyme 3-PG binding site (Fig 1) at the N-terminal domain; in
particular, the residues R38 and G166 are part of two helices, whereas the residue R65 is
located in a loop (Fig 1). R38 and R65 are involved in 3-PG binding; in particular, R65 NH1
and NH2 groups are involved in an electrostatic interaction with the carboxyl group of 3-PG,
whereas R65 Nε and NH2 groups acquire contacts with the phosphate group of 3-PG [43].
G166 is located in the 3-PG binding pocket interacting with the substrate C2 through its main
carboxylic group. M189 and A199 are located at the edges of the helix that represents the flexi-
ble hinge region that allow the two domains of the enzyme to approach each other during the
catalytic cycle (Fig 1). Residue V216 is located in a turn, in proximity of the nucleotide-binding
A214 residue; F241 is part of a helix, and they both belong to the MgADP binding pocket,
located at the protein C-terminal domain (Fig 1). Among the mutations studied, only R65W
involves a surface exposed residue, all others variants, R38M, G166D, M189I, A199V, V216F
and F241S are more buried. We generated recombinant protein for each of the identified
mutants using site directed mutagenesis and available bacterial expression systems. Introduc-
tion of these mutations resulted in soluble recombinant proteins and allowed us to study the
consequences of the mutations on PGK1 thermal and thermodynamic stability and the kinetic
activity.
Spectroscopic characterization of PGK1 wild type and variants
The conformation in solution of all PGK1 variants was studied by CD and fluorescence spec-
troscopy. The near-UV CD spectrum of PGK1 wild type represents the spectral contributions
of all aromatic residues and is characterized by a strong positive peak centred at around 292
nm, flanked by a shoulder at 286 nm and by negative contributions in the region between 255
and 270 nm, with two peaks centred at 262 and 268 nm (S1 Fig). R38M, G166D, A199V and
V216F display near-UV CD spectra closely similar to that of the wild type, except for a slight
difference at 277 nm observed for G166D (S1 Fig). Significant differences are observed in the
near-UV CD spectra of M189I, F241S and R65W (S1 Fig). In the case of M189I and F241S, the
contributions at 262 nm and 268 nm are positive; in addition, the spectrum of M189I loses
fine structure features in the region between 270 and 280 nm. The variant R65W shows a
near-UV CD spectrum that significantly differs from that of the wild type in intensity, consis-
tent with the substitution of an arginine residue with a tryptophan (S1 Fig). The fluorescence
spectra of wild type and variants are centred at the same maximum emission wavelength at
around 350 nm, characteristic of tryptophan contribution, with differences in the relative fluo-
rescence emission intensity which is significantly decreased for A199V and increased for
R65W, M189I and V216F (S1 Fig).
The far-UV CD spectra of PGK1 wild type and variants show the typical local minimum
contributions of alpha helical proteins at around 208 nm and at 222 nm (S1 Fig). The molar
ellipticity ratio at 222 and at 208 nm (Θ222/Θ208) is indicative of interhelical contacts present in
helix bundle and coiled coil structures and it is generally used to distinguish between coiled
coil helices (1.0) and non-interacting helices (0.8±0.9) [44,45]. TheΘ222/Θ208 is 1.2 for the
wild type, it is decreased to 1.1 only for the variants R38M and M189I and it is increased to 1.3
PGK1 variants in cancer
PLOSONE | https://doi.org/10.1371/journal.pone.0199191 July 11, 2018 8 / 22
for V216F (S1 Fig). Notably, in the case of M189I the far-UV dichroic activity is decreased
with respect to that of the wild type (S1 Fig). These differences in secondary structure may sug-
gest differences in interhelical interactions and dynamic fluctuation in solution for some of
PGK1 variants.
PGK1 wild type and variants: Kinetic properties and temperature
dependence of enzyme activity
Enzymatic assays of PGK1 wild type and variants. Kinetic properties of PGK1 wild type
and variants were investigated by monitoring the reverse reaction at 20ÊCat a fixed concentra-
tion of free Mg2+ and using 3-PG as variable substrate [33]. All the variants display altered
kinetic properties, in comparison with the wild type. The kinetic properties of wild type,
M189I and F241S, revealed a non Michaelis±Menten behaviour, as indicated by double recip-
rocal plots typical of substrate activation (data not shown). PGK1 specific activity, analysed
using 3-PG as variable substrate over the concentration range 0.05±15.0mM, is decreased for
all the variants with the exception of F241S that displays a two fold increase of activity
(Table 1). Notably, all the kinetic parameters indicate a significant decrease of the catalytic effi-
ciency (kcat/KM), particularly evident for R38M which displays a catalytic efficiency 10 milion
fold lower than that of the wild type. All the variants display an increase of 3-PG KM values,
particularly evident for F241S that shows a KM value 14-fold higher than that of the wild type
(Table 1).
Temperature dependence of enzyme activity. The kinase activity of PGK1 wild type and
variants was analysed as a function of temperature (10±42ÊC)using a low concentration of 3-
PG substrate (0.02 mM, well below the KM value) (Fig 2) to study the enzymatic release of sub-
strate and product that may be related to its flexibility. The optimal temperatures for catalysis,
in these conditions, were estimated to be 37ÊCfor the wild type and most of the variants,
around 35ÊCfor F241S, and around 40ÊCfor R38M and V216F (Table 2 and Fig 2). As shown
in Table 2, the lowest activation energy value (Ea) is that of the F241S variant (6.39 kcal/mol)
which is also the variant displaying a kcat higher than that of the wild type enzyme (213.0 vs
89.8 s-1). As mentioned before, the activation energies have been measured at a 3-PG concen-
tration of 0.02 mM, well below the KM value. At this substrate concentration, the enzyme is
not saturated, the complex enzyme-3-PG-MgATP may dissociate to form again the enzyme-
MgATP complex and free 3-PG or may catalyse the formation of the two products MgADP
and 1,3-BPG. The activation energy measured in these conditions reflects the enzymatic
Table 1. Kinetic parameters of PGK1 wild type and variants.
[PGK1]
(nM)
[3PG]
(mM)
KM
(mM)
kcat
(s-1)
kcat/ KM
(s-1 mM-1)
Vmax
(μM/min)
Specific activity
(μM/min•μg)
Wild type 0.18 0.05±15.0 0.40 ± 0.03 89.8 ± 1.5 224.5 0.97 248.7
R38M 9.04 x105 3.00±15.0 3.15 ± 0.40 (7.2 ± 0.5) x10-6 2.28x10-6 0.39 0.02
R65W 0.35 1.00±15.0 1.61 ± 0.13 23.7 ± 0.5 14.7 0.50 63.8
G166D 0.70 0.90±15.0 1.54 ± 0.15 5.9 ± 0.2 3.8 0.25 15.9
M189I 0.18 0.20±15.0 0.58 ± 0.50 30.5 ± 1.4 52.7 0.33 84.6
A199V 0.18 0.80±15.0 1.95 ± 0.15 76.6 ± 1.7 39.3 0.83 212.0
V216F 7.00 0.10±15.0 0.78 ± 0.05 1.9 ± 0.03 2.4 0.93 5.5
F241S 0.18 0.20±15.0 5.87 ± 0.7 213.0 ± 14.0 31.5 2.30 515.4
PGK1 activity was determined at 20ÊC,with 3-PG and 5 mMMgATP (fixed substrate concentration), as described in Materials and Methods. Kinetic parameters for
PGK1 activity were determined at 20ÊCby using at least at 10 different concentrations of 3-PG. Data are reported as the mean ± SE of the fit.
https://doi.org/10.1371/journal.pone.0199191.t001
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release of both the 3-PG substrate and the products and it may be related to the enzyme
flexibility.
Thermal stability
The thermal stability of PGK1 wild type and variants was studied between 20ÊCand 80ÊCby
continuously monitoring the ellipticity changes at 222 nm, where the main amplitude was
observed (S2 Fig). The thermal denaturation process is irreversible, as indicated by the spectra
Fig 2. Effect of temperature on kinase activity of PGK1 wild type and variants. (A) Temperature dependence of kinase activity of PGK1 wild type and variants. (B)
Non-linear fit of the temperature dependence of PGK1 activity to the Arrhenius equation Eq (1). Assays were performed under the conditions described in Materials
and Methods, using 0.18±12.0nM enzyme.
https://doi.org/10.1371/journal.pone.0199191.g002
Table 2. Effect of temperature on kinase activity of PGK1 wild type and variants.
Tmax (˚C) Ea (kcal/mol)
Wild type 37 11.47 ± 0.7
R38M 40 9.44 ± 0.34
R65W 37 10.03 ± 0.60
G166D 37 6.00 ± 0.30
M189I 37 8.50 ± 0.35
A199V 37 9.11 ± 0.39
V216F 40 12.82 ± 0.70
F241S 35 6.39 ± 0.41
Ea was determined by the Arrhenius equation Eq (1) in the temperature range between 10ÊCand the optimal
temperature of each protein.
https://doi.org/10.1371/journal.pone.0199191.t002
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measured at the end of the cooling phase that differ from those of the native proteins measured
at the beginning of the thermal transitions. The temperature-induced ellipticity changes at 222
nm occur in an apparent cooperative transition and overlap with the increase of the photomul-
tiplier tube voltage above 370 V (data not shown) at increasing temperature, suggesting that
the temperature-induced unfolding is accompanied by protein aggregation, as revealed by the
presence of a large amount of precipitate in the cuvette at the end of the cooling phase. The
parameter chosen to compare the transition curves of the proteins is the melting temperature
(Tm) defined as the midpoint of the denaturation process and calculated by plotting the first
derivative of the molar ellipticity values as a function of temperature (S2 Fig, inset). Tm values
range from 49.0ÊCto 53.5ÊCbeing 52.5ÊCthe Tm obtained for the wild type protein (Table 3).
The variant R65W shows the same Tm value of the wild type, a modest increase in Tm value is
observed for the variants G166D and A199V; all the other variants show Tm values lower than
that of the wild type, with F241S showing a Tm value three degrees below that of the wild type
(Table 3). Notably, differences in the amplitude observed for the thermal transitions of most of
the variants (S2 Fig) may be referred to the difference in the dichroic activity at 222 nm of
their corresponding native states, as also indicated in far-UV CD spectra reported in S1 Fig.
Urea-induced equilibrium unfolding transitions
PGK1 wild type and variants reversibly unfold in urea at 20ÊCin 20 mM Tris-HCl pH 8.0, 1
mM EDTA, 200 mM NaCl and 0. 2 mM DTT. The effect of increasing urea concentrations (0±
8 M) on the protein structure was analyzed by far-UV CD and fluorescence spectroscopy (S3
Fig). The fluorescence changes at increasing urea concentration were measured by calculating
the intensity averaged emission wavelength l, an integral measurement that depends both on
the position and the shape of the spectrum. The same samples used to monitor the fluores-
cence changes during the unfolding transitions were used to monitor the far-UV CD ellipticity
changes, to allow a direct comparison of the data. The urea-induced changes in 222 nm ellip-
ticity and in the emission fluorescence show a sigmoidal dependence on urea concentration
and follow an apparent two-state transition without any detectable intermediate (S3 Fig). The
unfolding process is fully reversible upon dilution of the denaturant either for the wild type
and the variant proteins. The denaturation curves relative to the apparent two-state equilib-
rium unfolding measured by far-UV CD and by fluorescence have been fitted to a two-state
Table 3. Melting temperatures and thermodynamic parameters for urea-induced unfolding equilibrium of PGK1 wild type and variants measured by far-UV CD
and fluorescence spectroscopy.
Tm (˚C) ΔGH2O (kcal/mol) m (kcal/mol•M) [Urea]0.5 (M)
CD ([Θ]222) Fluorescence ðλÞ CD ([Θ]222) Fluorescence ðλÞ CD ([Θ]222) Fluorescence ðλÞ
Wild type 52.5 8.29 ± 0.57 8.06 ± 0.46 3.54 ± 0.25 3.10 ± 0.17 2.34 2.60
R38M 51.5 6.91 ± 0.73 5.54 ± 0.37 3.54 ± 0.37 1.87 ± 0.12 1.95 2.96
R65W 52.5 7.04 ± 0.32 7.20 ± 0.66 3.07 ± 0.14 2.63 ± 0.24 2.29 2.73
G166D 53.0 4.19 ± 0.31 4.94 ± 0.29 2.33 ± 0.16 1.51 ± 0.09 1.75 3.27
M189I 50.5 4.87 ± 0.31 5.01 ± 0.48 2.36 ± 0.15 1.82 ± 0.17 2.06 2.75
A199V 53.5 7.14 ± 0.57 6.82 ± 0.72 3.41 ± 0.14 2.71 ± 0.22 2.23 2.63
V216F 52.0 6.45 ± 0.34 5.76 ± 0.54 2.99 ± 0.16 2.14 ± 0.20 2.16 2.69
F241S 49.0 3.02 ± 0.17 3.80 ± 0.26 2.06 ± 0.10 1.67 ± 0.11 1.47 2.27
Tm values were calculated by taking the first derivative of the ellipticity at 222 nm with respect to temperature. Urea-induced unfolding equilibrium data were measured
as described in Materials and Methods by monitoring the ellipticity at 222 nm ([Θ222]) and fluorescence intensity averaged emission wavelength ðlÞ. DGH2O andm
values were obtained from Eq (3); [Urea]0.5 was calculated from Eq (5). Data are reported as the mean ± SE of the fit.
https://doi.org/10.1371/journal.pone.0199191.t003
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model according to Eq (4) to obtain the thermodynamic parameters DGH2O, the free energy
change for unfolding in the absence of denaturant, andm, a parameter that refers to the
amount of protein surface area exposed to the solvent during unfolding (Table 3) [46]. Inter-
estingly, them values determined either for PGK1 wild type and variants are lower than that
predicted for a protein of 417 amino acid residues unfolded in urea [47, 48], suggesting a more
complex, presumably non-two state, unfolding process with undetectable intermediates (S3
Fig). DGH2O values of PGK1 variants are similar to those of the wild type, with the exception of
G166D, M189I and F241S that show a significant decrease in the thermodynamic parameters
(Table 3), mainly due to a decrease inm values. A decrease inm value may suggest either a
destabilization of the native state or the presence of unfolding intermediates, not detectable at
the equilibrium. The occurrence of undetectable unfolding intermediates may be the case of
R38M and G166D, as suggested by the non coincidence of the [Urea]0.5 values obtained by far-
UV CD and fluorescence changes, mainly due to the differences inm value (Table 3).
Structural analysis
We investigated the structure of PGK1 variants R38M, G166D, V216F and M189I in the pres-
ence of MgADP and 3-PG through X-ray crystallography in order to reveal possible local and
global variations with respect to the wild type protein. Two different crystallographic confor-
mations of PGK1 have been already identified: the partially closed conformation, able to bind
substrates, and the closed conformation, the catalytically competent state. Another form,
defined as open and that is the most populated conformation in solution, has been detected
through small-angle X-ray scattering [7]. It is interesting to note that all the mutants crystal-
lized in the partially closed conformation but only M189I crystallized even in the closed form,
suggesting that for the variants R38M, G166D and V216F the closed form is less favourable in
the crystallization conditions. The overall structure is conserved in all the mutants compared
to the wild type (Table 4, S4 Fig). The details of local variation are discussed case-by-case.
R38M variant. The residue R38 is placed in the N-terminal 3-PG binding domain and is a
residue important for the substrate binding and its correct positioning towards the co-sub-
strate MgADP (Fig 3). Moreover, together with residues K215 and K219, R38 is critical for the
charge balancing of the transition state, directly interacting with the transferring phosphate
group in the closed conformation of PGK1 [10].
The crystal structure of R38M contains ADP but does not contain 3-PG (Fig 3A), in line
with the role of R38. The absence of the 3-PG ligand could account even for the variant
Table 4. Superimposition between the PGK1 wild type and the crystallized variants.
Mutant Domain Role/position of mutated residue Conformation Ligands RMSD# (Å2)
R38M 3-PG-binding Binding of 3-PG, charge balancing in the transition state Partially closed MgADP vs 2ZGV: 0.23
vs 2XE7: 0.96
G166D 3-PG-binding Close to 3-PG COO- Partially closed MgADP vs 2ZGV: 0.62
vs 2XE7: 1.17
V216F ADP-binding Part of the catalytic loop 211±219 that favors closed conformation Partially closed MgADP, 3-PG vs 2ZGV: 0.60
vs 2XE7: 1.22
M189I Hinge N-terminal portion of the hinge Partially closed MgADP, 3-PG vs 2ZGV: 0.60
vs 2XE7: 1.18
Closed MgADP, 3-PG vs 2WZB: 0.25
RMSD#: root mean square deviation obtained from the superimposition of each variant with respect to wild type PGK1. 2ZGV: wild type binding MgADP; 2XE7: wild
type binding MgADP and 3-PG; 2WZB: wild type binding MgADP, 3-PG and MgF3
-
https://doi.org/10.1371/journal.pone.0199191.t004
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reluctance to crystallize in the closed form since the binding of both substrates is required for
the stabilization of this conformation. Taken together these observations justify the dramatic
effect of R38M mutation on kinetic parameters (see Table 1). Indeed, upon R38Mmutation
the KM increases from 0.40 to 3.15 mM and the turnover number strongly decreases from 89.8
to 7.2x10-6 s-1.
Apart from the mutation, in position 38, the local geometry of residues belonging to the
3-PG binding pocket is very similar to that of the wild type protein crystallized in the absence
of 3-PG (PDB code: 2ZGV, Fig 3B). The only differences between the two structures concern
the α-helix 374±382, visible in the R38M variant but not in the wild type 2ZGV structure, and
the position of the β-phosphate group, which in R38M points towards this helix (Fig 3A).
Fig 3. Detail of the 3-PG binding site in the variant R38M in comparison with PGK1 wild type. Overlap of R38M
variant (green) and PGK1 wild type crystallized (A) in the absence of 3-PG (PDB 2ZGV) (light grey) or (B) in the
presence of 3-PG (PDB: 2XE7) (grey). The view in B is rotated about 90Êanticlockwise with respect to A. ADP, 3-PG
and the residues involved in 3-PG binding are shown as sticks.
https://doi.org/10.1371/journal.pone.0199191.g003
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However, both the helix and the phosphate present some variability upon different PGK1
structures indicating that it could be dependent on crystallization conditions.
G166D variant. G166 is one of the residues lining the 3-PG binding site and its substitu-
tion for the bulky and negatively charged aspartate modifies the shape and the charge of the
substrate binding pocket. The structure of G166D (Fig 4) reveals that the aspartate Oδ is
engaged in a salt bridge with the R38 NH1 (OD-(D166)-NH1(Arg38) = 3.3 Å) altering its capa-
bility of interacting with 3-PG. These modifications of the pocket impair the binding of 3-PG,
that is not present in the structure, and the stabilization of the transition state through R38,
thus affecting both kcat (5.9 s
-1) with a 15-fold decrease, and KM (1.54 mM) increased 4- fold.
Fig 4. Detail of the 3-PG binding site in the variant G166D in comparison with PGK1 wild type. Overlap of G166D
variant (cyan) and PGK1 wild type crystallized (A) in the absence of 3-PG (PDB 2ZGV) (light grey) or (B) in the
presence of 3-PG (PDB: 2XE7) (grey). The view in B is rotated about 90Êanticlockwise with respect to A.
https://doi.org/10.1371/journal.pone.0199191.g004
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V216F variant. V216 belongs to the loop 214±219, close to the ADP-binding site. The
rearrangement of this loop has been suggested to be important for the enzyme transition to the
closed conformation upon binding of the two ligands [7]. Indeed, in the wild type structure in
complex with the MgADP ligand the loop assumes two conformations, promoting the reorien-
tation of K215 and D218, now ready to interact with γ-phosphate of 3-PG and D65, in the
closed conformation. In the V216F variant structure in complex with MgADP, the loop adopts
the same conformation as in apo-PGK1. As shown in Fig 5B, replacement of the valine with a
phenylalanine keeps the loop in the apo-like conformation since the aromatic residue tends to
stay buried. The lower mobility of the loop hampers the transition from the open to the closed
conformation affecting the enzyme catalytic activity (the kcat of the mutant is 1.9 s
-1, 45-fold
lower than that of the wild type). Conversely, no variation is found in ADP-binding. In fact, as
shown in Fig 5, the residues directly involved in the ADP binding (E343, G312, A214) and the
Mg2+ion bound through the β and γ-phosphate and D374 preserve the same positions as in the
wild type structure.
M189I variant. Residue 189 is part of the 189±201α-helix, the structural element that rep-
resents the hinge connecting the N-terminal 3-PG binding domain and the C-terminal ADP
binding domain. The structure of M189I has been solved both in open and closed conforma-
tion. Similarly to the other variants, M189I partially open structure is coincident to that of the
wild type but in this case both ADP and 3-PG are clearly visible. It should be noticed that in
the M189I variant structure the hydroxyl carboxylate moiety of the 3-PG is 90Ê-rotatedwith
respect to the position adopted in the wild type structure. This could be due to the presence, in
the active site, of a phosphate ion which may induce a change in the mode of 3-PG binding
(Fig 6A). Since M189I mutation causes neither overall nor local conformational change, the
KM of the mutant is very similar to that of the wild type protein (0.58 mM vs 0.40 mM) and the
kcat is only three times lower than that of the wild type protein (30.5 vs 89.8 s
-1). The structure
in the closed conformation was obtained in the same condition of the wild type protein (PDB
code: 2WZB). As shown in Fig 6B, the structure appear to be identical to the wild type ones;
also the position of the two ligands, ADP and 3-PG, is conserved. Interestingly, in the M189I
structure in the closed conformation MgF3
- is not present, therefore the transition complex,
evident in the wild type structure, is not formed in the M189I variant. Nevertheless, all the resi-
dues stabilizing the transition state are superposable between the wild type and mutant
structure.
Discussion
Phosphoglycerate kinase 1 (PGK1) is an ubiquitous enzyme expressed in all somatic cells that
plays a central role in glycolysis where it provides energy in form of ATP through the reversible
phosphotransfer reaction from 1,3-bisphosphoglycerate (1,3-BPG) to MgADP in order to pro-
duce 3-phosphoglycerate (3-PG) and MgATP in the presence of free magnesium. PGK1 is a
central enzyme in the cancer cells metabolism since they utilize preferentially glycolysis to pro-
duce ATP. Alteration of PGK1 levels has been reported in different cancer types and this
enzyme is considered as a negative prognostic marker [23]. In the general metabolic repro-
gramming of cancer cells, glycolytic enzymes play a pivotal role since many intermediates of
the glycolytic pathway may also be utilized for the increased biosynthetic demand of proliferat-
ing tumor cells [49]. Indeed, one of the consequence of the metabolic change in cancer cells is
the request of reducing equivalent for biosynthesis that can be provided through the deviation
of glycolysis intermediate in the shunt of pentose phosphate pathway [50].
In this study, we selected from the COSMIC database some somatic PGK1 single nucleotide
variants found in cancer tissues. The variants involve amino acid residues located in the
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enzyme 3-PG binding domain, in the nucleotide binding domain and in the hinge region con-
necting the two domains (Fig 1) and are different from those associated to PGK1 deficiency
and hereditary non-spherocytic haemolytic anaemia [33].
Independently from the position of the mutation on the protein, the main result of the ami-
noacid substitutions, object of this report, is a significant change in the variants catalytic
Fig 5. ADP binding site in the variant V216F in comparison with PGK1 wild type. (A) Detail of the binding of ADP
to V216F variant (orange). ADP and the residues involved in the interaction are depicted as sticks, Mg2+ ion as a green
sphere. (B) Superimpostition with wild type PGK1 crystallized with ADP and 3-PG (PDB: 2XE7) (grey), highlighting
how the mutation V216F impairs the movement of the loop 212±218.The residue V/F216 and ADP are shown as
sticks.
https://doi.org/10.1371/journal.pone.0199191.g005
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properties. All the variants display a reduced catalytic efficiency, particularly evident for the
variant R38M, that shows a decrease of eight order of magnitude of the kcat/KM value, mainly
due to a dramatic decrease of the turnover number (Table 1). As shown in the structure (Fig
3), R38 is located in the 3-PG binding site and interacts electrostatically with the carboxyl
group of 3-PG, hence it is critical for the positioning of the substrate in the catalytic site and
for the stabilization of the transition state (Fig 6B). Accordingly, the substitution of the R38
implies a dramatic decrease of the kcat and an increase of Km (see Table 1).
Mutation of the other residues involved in 3-PG binding, R65W, a positively charged argi-
nine with the non polar tryptophan, and G166D, a substitution of glycine with a negatively
Fig 6. M189I variant in comparison with PGK1 wild type. (A) Detail of the binding of 3-PG to M189I variant in the
partially-closed conformation (magenta) superimposed with partially-closed wild type PGK1 (PDB: 2XE7) (grey).
3-PG and the residues involved in the interaction are depicted as sticks. (B) Superimpostition of M189I variant in the
closed conformation (pink) with wild type PGK1 crystallized with ADP, 3-PG and MgF3
- (PDB: 2WBZ) (deep teal).
MgF3
- is shown as green and cyan spheres. Three water molecules (red spheres) bound to M189I mimic the position of
F- in MgF3
-.
https://doi.org/10.1371/journal.pone.0199191.g006
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charged residue, leads to an increase in Km values and, in the case of G166D, also to a reduced
turnover number. As shown in the structure, the introduction of a negatively charged residue
in the 3-PG binding site alters the affinity of the protein for the substrate (which is not found
in the structure) by occupying part of the binding site and by engaging the R38 in a new salt
bridge (Fig 4). Notably, the binding affinity for 3-PG is also significantly reduced in the variant
A199V, a mutation placed at the end of the hinge region. Regarding the mutants of the nucleo-
tide binding domain, V216F shows a decrease in the turnover number of about fifty fold, while
F241S a notable increase in the Km value accompanied by a two-fold increase in the turnover
number. Interestingly, the turnover numbers of M189I and A199V, both in the hinge region
and that of R65W, in the 3-PG binding site, are comparable to the turnover number of the
wild type, indicating that these mutations are not affecting the release of the product. The
reduced catalytic efficiency of all variants is supported by the local structural changes observed
in the X-ray structure of the crystallized variants that involve mutation of residues located
either in the 3-PG binding domain (R38M, G166D) or in the nucleotide binding site (V216F)
or in the hinge (M189I). Notably, the structural comparative analysis shows that the intro-
duced mutations do not cause large conformational changes in the protein tridimensional
structure but only local changes involving the mutated residues and their chemical surround-
ing. These local changes may be responsible for local differences in protein flexibility that
become evident in the values of activation energy that is decreased for all the cancer associated
variants, with the notable exception of V216F. In this variant, the introduction of a phenylala-
nine residue reinforces the hydrophobic interactions between the 211±219 loop and the 243±
263 region thereby stabilizing the C-terminal domain (Fig 5). This local stabilization, which
decreases the flexibility of the ATP binding site, is sufficient to determine the decrease of about
50-fold of the turnover number with respect to that of the wild type protein. The global effects
of local alterations are evident from the analysis of the thermodynamic parameters that point
to a destabilization of the native state, as indicated by the decrease of DGH2O values for all the
variants, particularly evident for G166D, M189I and F241S that involve mutation of residues
located in the 3-PG binding site, in the hinge region and in the nucleotide binding site, respec-
tively (Fig 1). Indeed, the significant decrease of them values observed for G166D, M189I and
F241S suggests a decrease of their surface area exposed to the solvent during unfolding.
The reduced catalytic properties and the decrease of the stability of PGK1 variants may sug-
gest that their expression in the neoplastic cells would significantly burden the metabolic flux
through the glycolytic pathway. Thus, metabolic intermediates may accumulate and be con-
verted in other products through alternative pathway, such as the pentose shunt, that could
supply for the biosynthetic need of the growing and proliferating tumor cell. On the other
hand, the occurrence of a ªglycolytic jamº may induce the cell to increase the uptake of glucose
[50].
Glycolytic enzymes may play additional roles other than sustaining the cell metabolism,
and translocate from the cytoplasm into the nucleus and/or mitochondria thus displaying
additional non-metabolic functions [51, 52]. Thus, mutations in a glycolytic enzyme may affect
not only its metabolic activity but also its alternative non-metabolic function. PGK1, as a
moonlighting enzyme, play alternative roles in different cellular compartments. In the mito-
chondria, PGK1 acts as a protein kinase and inhibits pyruvate metabolism promoting theWar-
burg effect [14]. In the nucleus, PGK1 binds to DNA polymerases α and εand increases the
synthesis of DNA [13]. In addition PGK1, when secreted in extracellular compartment by
tumor cells, binds plasmin thus permitting the cleavage of plasminogen in order to generate
the vascular inhibitor angiostatin [53].
It is noteworthy that some of the PGK1 variants found in cancer tissues involve residues
important for mitochondrial translocation, i.e. the region between residues 38 and 43. In this
PGK1 variants in cancer
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regard, R38, replaced with a methionine in the variant R38M, is placed in a critical position.
Similarly, A199V is in close proximity to S203 which, prior to mitochondria translocation, is
phosphorylated under hypoxia conditions [14].
In conclusion, the present paper discloses the structure and functional features of nsSNVs
of PGK1 found in cancer cells: R38M, R65W, G166D, M189I, A199V, V216F and F241S. We
succeed in solving the X-ray crystal structures of the variants with mutation in the N-terminal
region (R38M and G166D), in the C-terminal region (V216F) and in the hinge region
(M189I). We solved the structures of all these mutants in the partially closed conformation,
and we succeed to solve the structure of M189I also in the totally closed conformation.
Our study reveals that most of the PGK1 nsSNVs found in cancer tissues display a
decreased catalytic efficiency together with a destabilization of the native state. However, the
structural and functional data show only local changes around the mutated residues, without
large conformational changes in the protein structure. All these variants are less efficient with
respect to the wild type protein and the loss of efficiency is related, as shown by the crystals
structures, to the decreased affinity for the substrate as in the case of the R38M and G166D, or
to an increased local rigidity of the substrates binding sites as in the case of V216F and M189I.
A less efficient PGK1 in cancer cells may point to its moonlighting functions to satisfy cancer
cell proliferation and survival requirements.
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